Skip to main content
Erschienen in: Annals of Nuclear Medicine 10/2013

01.12.2013 | Original Article

Novel Tc-99m labeled ELR-containing 6-mer peptides for tumor imaging in epidermoid carcinoma xenografts model: a pilot study

verfasst von: Dae-Weung Kim, Woo Hyoung Kim, Myoung Hyoun Kim, Chang Guhn Kim

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

ELR-containing peptides targeting CXCR2 could be the excellent candidate for targeting ligand of molecular tumor imaging. In this study, we had developed two ELR-containing 6-mer peptides and evaluated the diagnostic performance of Tc-99m labeled 6-mer peptides as a molecular imaging agent in murine models bearing KB epidermoid carcinoma.

Methods

Peptides were synthesized using Fmoc solid phase peptide synthesis. Radiolabeling efficiency with Tc-99m was evaluated using instant thin-layer chromatography. In KB epidermoid cancer-bearing mice, gamma images had acquired and tumor-to-muscle uptake ratio was calculated. Competition and biodistribution studies had performed.

Results

Two 6-mer peptides, ELR-ECG and ECG-ELR were successfully synthesized. After radiolabeling procedures with Tc-99m, the complex Tc-99m ELR-ECG and Tc-99m ECG-ELR were prepared in high yield. In the gamma camera imaging of murine model, Tc-99m ELR-ECG was substantially accumulated in the subcutaneously engrafted tumor and tumor uptake had been suppressed by the free ELR co-injection. However, Tc-99m ECG-ELR was minimally accumulated in the tumor.

Conclusions

Two ELR-containing 6-mer peptides, ELR-ECG and ECG-ELR, were developed as a molecular imaging agent to target CXCR2 of epidermoid carcinoma. Tc-99m ELR-ECG had showed significant uptake in tumor and it was good candidate for a tumor imaging.
Literatur
1.
Zurück zum Zitat Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006;42:768–78.PubMedCrossRef Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006;42:768–78.PubMedCrossRef
2.
Zurück zum Zitat Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–45.PubMedCrossRef Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–45.PubMedCrossRef
3.
Zurück zum Zitat Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8.PubMed Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8.PubMed
4.
Zurück zum Zitat Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol. 2000;165:5269–77.PubMed Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol. 2000;165:5269–77.PubMed
5.
6.
7.
Zurück zum Zitat Nannuru KC, Sharma B, Varney ML, Singh RK. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog. 2011;10:40.PubMedCentralPubMedCrossRef Nannuru KC, Sharma B, Varney ML, Singh RK. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog. 2011;10:40.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000;275:6868–75.PubMedCrossRef Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000;275:6868–75.PubMedCrossRef
9.
Zurück zum Zitat Wong E, Fauconnier T, Bennett S, Valliant J, Nguyen T, Lau F, et al. Rhenium(V) and Technetium(V) oxo complexes of an N(2)N’S peptidic chelator: evidence of interconversion between the Syn and Anti conformations. Inorg Chem. 1997;36:5799–808.PubMedCrossRef Wong E, Fauconnier T, Bennett S, Valliant J, Nguyen T, Lau F, et al. Rhenium(V) and Technetium(V) oxo complexes of an N(2)N’S peptidic chelator: evidence of interconversion between the Syn and Anti conformations. Inorg Chem. 1997;36:5799–808.PubMedCrossRef
10.
Zurück zum Zitat Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235–68.PubMedCrossRef Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235–68.PubMedCrossRef
11.
Zurück zum Zitat Rajagopalan L, Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J Biol Chem. 2004;279:30000–8.PubMedCrossRef Rajagopalan L, Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J Biol Chem. 2004;279:30000–8.PubMedCrossRef
12.
Zurück zum Zitat Zhu A, Shim H. Current molecular imaging positron emitting radiotracers in oncology. Nucl Med Mol Imaging. 2011;45:1–14.CrossRef Zhu A, Shim H. Current molecular imaging positron emitting radiotracers in oncology. Nucl Med Mol Imaging. 2011;45:1–14.CrossRef
13.
Zurück zum Zitat Kim DW, Kim CG. Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions. Clin Breast Cancer. 2013;13:196–201.PubMedCrossRef Kim DW, Kim CG. Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions. Clin Breast Cancer. 2013;13:196–201.PubMedCrossRef
14.
Zurück zum Zitat Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003;181:359–65.PubMedCrossRef Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003;181:359–65.PubMedCrossRef
15.
Zurück zum Zitat Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann Nucl Med. 2006;20:1–11.PubMedCrossRef Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann Nucl Med. 2006;20:1–11.PubMedCrossRef
16.
Zurück zum Zitat Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, et al. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem. 2010;285:9114–23.PubMedCentralPubMedCrossRef Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, et al. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem. 2010;285:9114–23.PubMedCentralPubMedCrossRef
Metadaten
Titel
Novel Tc-99m labeled ELR-containing 6-mer peptides for tumor imaging in epidermoid carcinoma xenografts model: a pilot study
verfasst von
Dae-Weung Kim
Woo Hyoung Kim
Myoung Hyoun Kim
Chang Guhn Kim
Publikationsdatum
01.12.2013
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 10/2013
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-013-0766-9

Weitere Artikel der Ausgabe 10/2013

Annals of Nuclear Medicine 10/2013 Zur Ausgabe